# TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

> **NCT03506802** · PHASE1 · WITHDRAWN · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- HLA-A*0201 Positive Cells Present
- NY-ESO-1 Positive Tumor Cells Present
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **RADIATION:** 18F-FHBG
- **BIOLOGICAL:** Aldesleukin
- **BIOLOGICAL:** Cellular Therapy
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Filgrastim
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **PROCEDURE:** Leukapheresis
- **DRUG:** Melphalan
- **DRUG:** Plerixafor
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT03506802
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-07-10
- **Primary completion:** 2019-06-25
- **Final completion:** 2019-06-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No Participants Enrolled
- **Last updated:** 2020-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03506802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03506802, "TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03506802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*